Pfizer-backed Vedanta Biosciences lands $106M for PhIII in C. diff, PhII in IBD
Vedanta Biosciences has secured the cash it needs to run a Phase III in Clostridioides difficile and a mid-stage trial in ulcerative colitis, with runway through 2025, CEO Bernat Olle told Endpoints News.
The microbiome biotech nabbed $106.5 million to test whether VE303 can work for preventing recurrent C. diff, which leads to inflammation of the colon, with a different approach than Ferring Pharmaceuticals’ recently approved fecal-based drug implant Rebyota and Seres Therapeutics’ candidate, set for an FDA approval decision on Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.